Vitamin K deficiency in CKD patients: A modifiable risk factor for vascular calcification?

Kidney International

Volumn 76, Issue 1, 2009, Pages 18-22

  Krueger, Thilo ^a,b   Westenfeld, Ralf ^b   Ketteler, Markus ^c   Schurgers, Leon J ^d   Floege, Jürgen ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c KLINIKUM COBURG   (Germany)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Dialysis; Matrix Gla protein; Vascular calcification; Vitamin K

Indexed keywords

GROWTH ARREST SPECIFIC PROTEIN 6; HOMARYLAMINE; MENADIONE; MENAQUINONE; MK 4; OSTEOCALCIN; PHYTOMENADIONE; UNCLASSIFIED DRUG; VITAMIN K GROUP;

ARTERY MEDIA; BLEEDING; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; HIGH RISK PATIENT; HUMAN; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SUPPLEMENTATION; VITAMIN K DEFICIENCY;

CALCINOSIS; HUMANS; KIDNEY FAILURE, CHRONIC; MODELS, BIOLOGICAL; RISK FACTORS; VASCULAR DISEASES; VITAMIN K DEFICIENCY;

EID: 67449146899     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.126     Document Type: Short Survey

References (43)

1. Amann K. Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1599-1605.
2. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003; 18: 1731-1740.
3. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438-441.
4. Lehto S, Niskanen L, Suhonen M et al. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulindependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16: 978-983.
5. Ketteler M, Schlieper G, Floege J. Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 2006; 47:1027-1034.
6. Luo G, Ducy P, McKee MD et al. Spontaneous calcification of arteries and cartilage In mice lacking matrix GLA protein. Nature 1997; 386: 78-81.
7. Meier M, Weng LP, Alexandrakls E et al. Tracheobronchial stenosis In Keutel syndrome. Eur Respir J 2001; 17: 566-569.
8. Murshed M, Schinke T, McKee MD et al. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004; 165:625-630.
9. Shanahan CM. Mechanisms of vascular calcification in renal disease. Clin Nephrol 2005; 63: 146-157.
10. Zebboudj AF, lmura M, Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 2002; 277: 4388-4394.
11. Schurgers LJ, Teunissen KJ, Knapen MH et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005; 25: 1629-1633.
12. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae In rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400-1407.
13. Schurgers LJ, Teunissen KJ, HamulyakKef al. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood 2007; 109: 3279-3283.
14. Spronk HM, Soute BA, Schurgers U et al. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J Vasc Res 2003; 40: 531-537.
15. Melaragno MG, Cavet ME, Yan C et al. Gas6 inhibits apoptosis in vascular smooth muscle: role of AxI kinase and Akt. J Mol Cell Cardiol 2004; 37: 881-887.
16. Konlshi A, Aizawa T, Mohan A et al. Hydrogen peroxide activates the Gas6-Axl pathway In vascular smooth muscle cells. J Biol Chem 2004; 279: 28766-28770.
17. Nakano T, Kawamoto K, Kishino J et al. Requirement of gammacarboxyglutamic acid residues for the biological activity of Gas6: contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. Biochem J 1997; 323: 387-392.
18. Collett GD, Sage AP, Kirton JP et al. Axl/phosphatidylinositol 3-kinase signaling inhibits mineral deposition by vascular smooth muscle cells. Circ Res 2007; 100: 502-509.
19. Fernandez-Fernandez L, Bellido-Martin L, Garcia dF. Growth arrest-specific gene 6 (GAS6). An outline of its role in haemostasis and inflammation. Thromb Haemost 2008; 100: 604-610.
20. Suttie JW. The importance of menaquinones in human nutrition. Annu Rev Nutr 1995; 15:399-417.
21. Thijssen HH, Vervoort LM, Schurgers LJ et al. Menadione is a metabolite of oral vitamin K. Br J Nutr 2006; 95: 260-266.
22. Luukinen H, Kakonen SM, Pettersson K et al. Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res 2000; 15: 2473-2478.
23. Binkley NC, Suttie JW. Vitamin K nutrition and osteoporosis. J Nutr 1995; 125: 1812-1821.
24. Feskanich D, Weber P, Willett WC et al. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr 1999; 69: 74-79.
25. Braam LA, Knapen MH, Geusens P et al. Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calcif Tissue lnt 2003; 73: 21-26.
26. Knapen MH, Schurgers LJ, Vermeer C. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osfeoporos lnt 2007; 18: 963-972.
27. Naves M, Rodriguez-Garcia M, Diaz-Lopez JB et al. Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporos lnt 2008; 19: 1161-1166.
28. Booth SL, Dallai G, Shea MK et al. Effect of vitamin K supplementation on bone loss In elderly men and women. J Clin Endocrinol Metab 2008; 93: 1217-1223.
29. Geleijnse JM, Vermeer C, Grobbee DE et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr 2004; 134: 3100-3105.
30. Braam LA, Hoeks AP, Brouns F et al. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost 2004; 91: 373-380.
31. Gage BF, Birman-Deych E, Radford MJ et al. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 2006; 166: 241-246.
32. Koos R, Mahnken AH, Muhlenbruch G et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol 2005; 96: 747-749.
33. Holden RM, Sanfilippo AS, Hopman WM et al. Warfarin and aortic valve calcification in hemodialysis patients. J Nephrol 2007; 20: 417-422.
34. Mehta RL, Scott G, Sloand JA et al. Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis. Am J Med 1990; 88: 252-257.
35. Malyszko J, Wolczynski S, Skrzydlewska E et al. Vitamin K status in relation to bone metabolism in patients with renal failure. Am J Nephrol 2002; 22: 504-508.
36. Pilkey RM, Morton AR, Boffa MB et al. Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis 2007; 49: 432-439.
37. Cranenburg EC, Vermeer C, Koos R et al. The Circulating Inactive Form of Matrix Gla Protein (ucMGP) as a Biomarker for Cardiovascular Calcification. J Vasc Res 2008; 45: 427-436.
38. Hermans MM, Vermeer C, Kooman JP et al. Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Blood Purif 2007; 25: 395-401.
39. Cranenburg EC, Brandenburg VM, Vermeer C et al. Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost 2009; 101: 359-366.
40. Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcification Inhibitor in need of vitamin K. Thromb Haemost 2008; 100: 593-603.
41. Shiraki M, Shiraki Y, Aoki C et al. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000; 15: 515-521.
42. Nakashima A, Yorioka N, Dol S et al. Effects of vitamin K2 in hemodialysis patients with low serum parathyroid hormone levels. Bone 2004; 34: 579-583.
43. Stafford DW. The vitamin K cycle. J Thromb Haemost 2005; 3: 1873-1878.